anti-BCMA in-vivo CAR therapy (Orna Therapeutics)

N/A

Report date: 2026/04/23 17:57:57

Base Information

Drug Nameanti-BCMA in-vivo CAR therapy (Orna Therapeutics)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy > Chimeric antigen receptor Macrophages therapy +[6] 
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsLymphoma, B-CellLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesOrna Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrna Therapeutics IncShanghai Simnova Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, B-CellLeukemia, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A